WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1997011686) REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1997/011686    International Application No.:    PCT/US1996/015300
Publication Date: 03.04.1997 International Filing Date: 25.09.1996
Chapter 2 Demand Filed:    04.04.1997    
IPC:
A61K 9/14 (2006.01), A61K 45/06 (2006.01), A61K 49/04 (2006.01), A61K 49/18 (2006.01)
Applicants: NANOSYSTEMS L.L.C. [US/US]; Building 1, 1250 South Collegeville Road, Collegeville, PA 19426 (US)
Inventors: DE GARAVILLA, Lawrence; (US).
LIVERSIDGE, Elaine, M.; (US).
LIVERSIDGE, Gary, G.; (US)
Agent: WEST, Paul, B.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US)
Priority Data:
60/004,488 29.09.1995 US
08/696,754 14.08.1996 US
Title (EN) REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS
(FR) DIMINUTION DE REACTIONS PHYSIOLOGIQUES NEGATIVES PROVOQUEES PAR DES FORMULATIONS NANOPARTICULAIRES ADMINISTREES PAR VOIE INTRAVEINEUSE
Abstract: front page image
(EN)Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pretreating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.
(FR)L'invention concerne des procédés d'administration intraveineuse de formulations médicamenteuses nanoparticulaires à un mammifère, permettant d'éviter l'apparition d'effets négatifs hémodynamiques par limitation du taux et de la concentration des nanoparticules dans les formulations, par traitement préalable du sujet à l'histamine, ou par traitement préalable du sujet avec une quantité désensibilisante desdites formulations.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN.
African Regional Intellectual Property Organization (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)